PPD
OCTOBER 18, 2023
With the depth of knowledge to support all types of pharmaceutical products across all phases of development, we provide services ranging from end-to-end assay development to platform expansion, designed with the client’s timeline and budget in mind. Stay ahead of the curve with a great GMP/CMC contract laboratory partner.
PerkinElmer
NOVEMBER 12, 2020
In drug development, assays are test systems that gauge the effects of chemical compounds on certain cellular, molecular, or biochemical processes. They are a vital step in modern pharma research that pushes drugs to market faster. These are just three of the steps to take toward reliable and replicable assay development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Alta Sciences
AUGUST 21, 2023
Efficient Characterization of ADME A critical feature of the bioanalytical platform selected for a drug development program is how well it characterizes the ADME (absorption, distribution, metabolism, excretion) of your molecule of interest. Why Partner With Altasciences for Your Bioanalytical Projects?
Drug Target Review
NOVEMBER 1, 2023
We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production. In 2019 he became Reader in Structural Biology and Cancer Drug Discovery. Although we are an academic centre we work very much like industry.
Sygnature Discovery
JANUARY 17, 2023
About SB Drug Discovery SB Drug Discovery is an industry leader in specialist contract research, providing critical data for novel drug development through cell line generation, assay development and compound screening services. SB is based in Glasgow and employs 55 people.
FDA Law Blog: Drug Discovery
JANUARY 4, 2023
The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development.
Drug Target Review
OCTOBER 3, 2024
In 2024 alone, almost 50 antibody drug candidates are anticipated to enter regulatory review, the majority of which are mAbs. Aside from the advent of complex antibody-based drugs, the industry is facing some additional changes which are shaping drug development. Adapted from Harth S et al. (8) 8) under a CC BY-NC-ND 4.0.
Expert insights. Personalized for you.
52 
Let's personalize your content